Literature DB >> 25270506

Accuracy of ultrasonography performed by examiners with varied training and experience in predicting specific pathology of adnexal masses.

A Sayasneh1, J Kaijser, J Preisler, A A Smith, F Raslan, S Johnson, R Husicka, L Ferrara, C Stalder, S Ghaem-Maghami, D Timmerman, T Bourne.   

Abstract

OBJECTIVES: To assess the diagnostic performance of subjective assessment by Level II ultrasound examiners in predicting the specific histology of adnexal masses.
METHODS: The women included in this prospective multicenter cross-sectional study were older than 16 years of age and had at least one adnexal mass. They underwent transvaginal sonography (TVS) performed by Level II examiners, all of whom were familiar with the International Ovarian Tumor Analysis (IOTA) group definitions of ultrasound features of ovarian masses. The final outcome was histology. Specific diagnoses were categorized into 16 groups. Agreement between subjective assessment and final histology was measured using unweighted kappa coefficients. Sensitivities and specificities were obtained for subjective assessment.
RESULTS: Of the 1279 women who underwent TVS, 313 were included in the final analysis. Overall agreement (16 × 16 table) between subjective assessment and histology was moderate, with a Cohen's kappa coefficient of 0.59 (95% CI, 0.53-0.65). The specificity of subjective assessment ranged between 91% and 100% for all histological subgroups. Highest sensitivities were achieved in the diagnosis of simple cysts (100% (95% CI, 61-100%)), hydrosalpinges (100% (95% CI, 34-100%)), mature teratomas (88% (95% CI, 74-96%)), endometriomas (75% (95% CI, 61-85%)), ovarian fibromas (88% (95% CI, 47-100%)), tubo-ovarian abscesses (88% (95% CI, 47-100%)) and serous cystadenocarcinomas (82% (95% CI, 66-93%)). Serous cystadenomas were misdiagnosed most commonly (40.5%). The sensitivity of subjective assessment in diagnosing adnexal torsion was 54% (95% CI, 25-81%); the 17 confirmed and/or suspected cases of adnexal torsion were not included in the 313 cases examined and analyzed for diagnostic performance.
CONCLUSION: Overall, subjective assessment by Level II examiners was good for the detection of simple cysts, endometriomas, mature teratomas, hydrosalpinges, fibroma, tubo-ovarian abscess and serous cystadenocarcinomas.
Copyright © 2014 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ovarian cancer; ovarian neoplasm; ovary; ultrasonography; visual pattern recognition

Mesh:

Year:  2015        PMID: 25270506     DOI: 10.1002/uog.14675

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  6 in total

1.  A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer.

Authors:  James P Beirne; Alan Gilmore; Caitríona E McInerney; Aideen Roddy; W Glenn McCluggage; Ian J G Harley; M Abdullah Alvi; Kevin M Prise; Darragh G McArt; Paul B Mullan
Journal:  Comput Struct Biotechnol J       Date:  2022-06-17       Impact factor: 6.155

2.  Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies.

Authors:  J Kaijser
Journal:  Facts Views Vis Obgyn       Date:  2015

Review 3.  Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.

Authors:  Laura Feeney; Ian Jg Harley; W Glenn McCluggage; Paul B Mullan; James P Beirne
Journal:  World J Clin Oncol       Date:  2020-11-24

4.  Role of Sonographic Gray-Scale Pattern Recognition in the Diagnosis of Adnexal Masses.

Authors:  Jyothi Shetty; Grishma Reddy; Deeksha Pandey
Journal:  J Clin Diagn Res       Date:  2017-09-01

5.  Biomarkers and Strategies for Early Detection of Ovarian Cancer.

Authors:  Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-13       Impact factor: 4.254

6.  Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.

Authors:  Núria Carreras-Dieguez; Ariel Glickman; Meritxell Munmany; Georgina Casanovas; Núria Agustí; Berta Díaz-Feijoo; Adela Saco; Beatriz Sánchez; Lydia Gaba; Martina Aida Angeles; Jaume Pahisa; Esther Fernández-Galán; Aureli Torné; Pere Fusté
Journal:  Diagnostics (Basel)       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.